On sampling of fragment space

被引:24
作者
Makara, Gergely M. [1 ]
机构
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA
关键词
D O I
10.1021/jm0700316
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based lead discovery has over the years matured into an attractive alternative to high-throughput screening (HTS) for lead generation. Several techniques for screening libraries of typically 10(3)-10(4) fragments have been reported. In this work, the practical success rates that can be expected from the screening of fragment-like libraries was investigated via interrogating medicinal chemistry databases for several programs with virtual libraries created from commercially available reagents or with libraries of commercially available fragments. The results suggest that hits more potent than typically discovered in today's fragment-based screens can consistently be identified from realistically accessible compound sets under screening conditions similar to commonly used HTS protocols.
引用
收藏
页码:3214 / 3221
页数:8
相关论文
共 31 条
[21]   Aminomethylpyrimidines as novel DPP-IV inhibitors:: A 105-fold activity increase by optimization of aromatic substituents [J].
Peters, JU ;
Weber, S ;
Kritter, S ;
Weiss, P ;
Wallier, A ;
Boehringer, M ;
Hennig, M ;
Kuhn, B ;
Loeffler, BM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (06) :1491-1493
[22]   3-[3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine:: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist [J].
Poon, SF ;
Eastman, BW ;
Chapman, DF ;
Chung, J ;
Cramer, M ;
Holtz, G ;
Cosford, NDP ;
Smith, ND .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (22) :5477-5480
[23]   Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase [J].
Powers, RA ;
Morandi, F ;
Shoichet, BK .
STRUCTURE, 2002, 10 (07) :1013-1023
[24]   Drugs, leads, and drug-likeness: An analysis of some recently launched drugs [J].
Proudfoot, JR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (12) :1647-1650
[25]   Discovery of potent inhibitors of dihydroneopterin aldolase using crystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization [J].
Sanders, WJ ;
Nienaber, VL ;
Lerner, CG ;
McCall, JO ;
Merrick, SM ;
Swanson, SJ ;
Harlan, JE ;
Stoll, VS ;
Stamper, GF ;
Betz, SF ;
Condroski, KR ;
Meadows, RP ;
Severin, JM ;
Walter, KA ;
Magdalinos, P ;
Jakob, CG ;
Wagner, R ;
Beutel, BA .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1709-1718
[26]   Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity [J].
Smith, ND ;
Poon, SF ;
Huang, DH ;
Green, M ;
King, C ;
Tehrani, L ;
Roppe, JR ;
Chung, J ;
Chapman, DP ;
Cramer, M ;
Cosford, NDP .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (22) :5481-5484
[27]   Estimation of aqueous solubility of chemical compounds using E-state indices [J].
Tetko, IV ;
Tanchuk, VY ;
Kasheva, TN ;
Villa, AEP .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (06) :1488-1493
[28]   Structure-based optimization of a non-β-lactam lead results in inhibitors that do not up-regulate β-lactamase expression in cell culture [J].
Tondi, D ;
Morandi, F ;
Bonnet, R ;
Costi, MP ;
Shoichet, BK .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (13) :4632-4639
[29]   Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors [J].
Ward, RA ;
Perkins, TDJ ;
Stafford, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6991-6996
[30]  
WIEDEMAN PE, 2005, DRUG DISCOV TODAY, V2, P143